Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26689958 | 0.84 | ALOX15 (0.48) | ALDH1A1POLBKMT2AALOX15SMN1; SMN2 | |
| SCHEMBL3596352 | 0.81 | MAPT (0.45) | ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL3596350 | 0.81 | MAPT (0.45) | ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL257250 | 0.79 | ALDH1A1 (0.62) | ALDH1A1POLBKMT2AALOX15SMN1; SMN2 | |
| SCHEMBL11191069 | 0.77 | CYP1A2 (0.55) | ALDH1A1KMT2AALOX15SMN1; SMN2HPGD | |
| SCHEMBL4470824 | 0.77 | HCAR2 (0.41) | ALDH1A1POLBKMT2ASMN1; SMN2USP2 | |
| SCHEMBL2913063 | 0.77 | ALDH1A1 (0.61) | ALDH1A1POLBKMT2AALOX15SMN1; SMN2 | |
| SCHEMBL6218114 | 0.76 | CYP2C9 (0.47) | ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL6218116 | 0.76 | CYP2C9 (0.47) | ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4 | |
| SCHEMBL24392298 | 0.76 | CYP1A2 (0.49) | ALDH1A1KMT2AALOX15SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | OKADA MAKOTO (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-1244672-B1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6908930-B2 | 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6610688-B2 | For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer | SUGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1244672-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046196-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CSNK1A1, CDK2 | ALDH1A1 3371/4885POLB 3650/4885KMT2A 685/4885 |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CDK7, CDK2 | ALDH1A1 3066/4885POLB 3163/4885KMT2A 955/4885 |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | PDE9A, ADCY9, PDE3A | ALDH1A1 858/4885POLB 2322/4885KMT2A 1460/4885 |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | ALDH1A1 1387/4885POLB 2232/4885KMT2A 1913/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | ALDH1A1 858/4885POLB 2322/4885KMT2A 1460/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | ALDH1A1 484/4885POLB 999/4885KMT2A 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.